Anvar

Quick links to important sections

Anvar

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Anvar

Property Description
Active ingredient Propofol (2,6-diisopropylphenol)
Form Sterile, injectable oil-in-water emulsion
Pharmacological class Systemic General Anesthetic
Common use Inducing/maintaining unconsciousness
Origin Synthetic substituted phenol

What Type of Medicine is Anvar (Propofol) and its Chemical Identity?

The medication referred to as Anvar, which contains the active compound Propofol, is classified as a rapidly acting Systemic General Anesthetic and belongs to the pharmacological class of non-barbiturate sedative-hypnotic agents. Its chemical identity is Propofol (2,6-diisopropylphenol), a synthetic substituted phenol compound, which functions as a potent Central Nervous System (CNS) depressant. This classification is based on the drug's ability to quickly and reversibly suppress brain activity, leading to a state of controlled sleep or unconsciousness. The unique non-barbiturate structure is a key differentiator, contributing to the drug’s swift recovery profile compared to older agents.

Composition and Pharmaceutical Form

Propofol is manufactured as a distinctive white, milky, sterile injectable emulsion that must be administered strictly via the Intravenous (IV) Route of administration. This pharmaceutical form is critical because the active ingredient, Propofol, is highly lipid-soluble and nearly water-insoluble. It must therefore be delivered within an aqueous oil-in-water emulsion base, which typically includes excipients like soybean oil and egg phosphatides. This lipid-based formulation is necessary to facilitate the drug's rapid distribution across the blood-brain barrier.

General Purpose and Intended Function

The general purpose of Propofol is to achieve a rapid, controlled state of profound sedation or unconsciousness when medical intervention is necessary. Due to its potent and immediate CNS depressant effect, it serves as the foundational agent for the induction of general anesthesia prior to major surgery. Furthermore, it is commonly utilized to provide continuous, adjustable procedural sedation for patients who require ongoing monitoring, such as those receiving mechanical ventilation in a critical care environment.

Regulatory References

  1. Propofol: MedlinePlus Drug Information
  2. Propofol: StatPearls - NCBI Bookshelf

What side effects are possible with Anvar?

Possible Side Effects and Safety Information

The safety profile for the medicine Anvar, which contains Propofol, is organized in regulatory documents based on the frequency and the physiological systems affected. These classifications establish the formal framework for understanding the medicine's documented risks.


Adverse Reaction Classifications

Side effects are categorized by frequency, ranging from very common to rare. The most frequently documented events include local pain, burning, or stinging at the injection site (Very Common). Adverse effects classified as Common include significant drops in blood pressure (arterial hypotension) and transient cessation of breathing (apnea), along with slow heart rate (bradycardia), and instances of nausea and vomiting during recovery. Less common reactions include the formation of blood clots (thrombosis) or inflammation of the vein (phlebitis).


Systemic Safety Considerations

Adverse reactions are primarily associated with the Vascular Disorders (e.g., hypotension) and Respiratory, Thoracic, and Mediastinal Disorders (e.g., apnea) systems. Other documented effects involve Nervous System Disorders (e.g., involuntary movements) and Metabolism and Nutrition Disorders (e.g., hyperlipemia).


Serious Adverse Reactions and Restrictions

Regulatory documents explicitly list rare but serious adverse reactions, including Anaphylaxis and the life-threatening Propofol Infusion Syndrome (PRIS), which involves severe metabolic acidosis and rhabdomyolysis. The risk of PRIS is noted to be strongly associated with prolonged, high-dose continuous infusion.

Safety notes specify particular caution in older adults, who are at increased risk for profound cardiorespiratory depression. Furthermore, the use of Propofol for ICU sedation is contraindicated in children 16 years of age and younger.

Overdose and Emergency Response

The official regulatory documentation for Anvar (Propofol) states that overdosage is primarily defined by the presentation of profound cardiorespiratory depression. This condition results from excessively high drug concentrations and manifests clinically as severe arterial hypotension, apnea (cessation of breathing), bradycardia, and decreased cardiac output. These severe physiological disruptions require immediate and urgent medical intervention.

When to Seek Urgent Help

Immediate cessation of administration of Anvar and prompt medical attention are officially mandated upon any suspicion of overdose or the development of these life-threatening manifestations. Hospital monitoring is required, as there is no specific pharmacological antidote documented in regulatory labels for Propofol.

Overdose management is restricted to symptomatic and supportive therapy. Procedures include establishing assisted or controlled mechanical ventilation for respiratory depression and administering fluid replacement or vasoconstrictors to manage circulatory depression.

A life-threatening complication associated with prolonged, high-dose exposure is Propofol Infusion Syndrome (PRIS). This severe outcome is officially documented to lead to severe metabolic acidosis, rhabdomyolysis, cardiac failure, and potentially death. Patients at risk, such as the elderly or those with severe systemic disease, are documented as having increased vulnerability to these severe effects. The official profile underscores the necessity for continuous monitoring of cardiac, respiratory, and metabolic status during any overdose event.

Therapeutic Uses of Anvar

Propofol is generally used in acute medical settings to manage symptom patterns and conditions that require controllable suppression of the central nervous system. Its core applications are defined by the need for deep, protective sedation and a swift recovery profile. The core applications align with established therapeutic uses for this compound in contexts like general anesthesia and critical care.

The medicine is used for managing severe symptomatic distress across several clinical domains, including general anesthesia for major surgery, deep procedural sedation for interventional and diagnostic procedures, continuous ICU sedation for mechanically ventilated patients, and the high-acuity treatment of refractory status epilepticus (prolonged seizure activity).

It is commonly applied in scenarios where short-term, profound symptomatic assistance is needed. The primary benefit is supporting a state of controlled sleep and unawareness during these acute medical procedures. Furthermore, it supports the management of severe agitation and anxiety, promoting patient calmness and offering crucial supportive relief in critical care. It may assist with supporting functional stability and contributes to the easing of certain symptoms like postoperative nausea and vomiting.

Quick Fact: Relief for Severe Agitation Propofol is commonly applied for continuous sedation of critically ill patients in the Intensive Care Unit (ICU) who are receiving mechanical ventilation, supporting patient management by easing intense physical discomfort.

Eligibility and Restrictions for Use

Who Can and Cannot Use Anvar (Propofol)

The eligibility for Propofol use is strictly defined by regulatory criteria, encompassing specific allergies, age limits, and pre-existing health conditions.

Eligibility Classification Official Regulatory Status
Absolute Contraindication Contraindicated in patients with a known hypersensitivity to Propofol or components of the emulsion, including allergies to egg or soy products.
ICU Sedation Prohibition Contraindicated for sedation in pediatric patients aged 16 years or younger in the Intensive Care Unit setting.

Age-Related Rules Adults (18 years and older) are approved for general anesthesia, MAC sedation, and ICU sedation. For pediatric anesthesia, the drug is officially approved for maintenance starting at 2 months of age and for induction starting at 3 years of age. Use for Monitored Anesthesia Care (MAC) sedation has not been established in children.

Conditional and Restricted Use Use is permitted but requires caution and often dose reduction in the elderly and in patients with severe systemic disease (ASA III/IV), due to potential cardiorespiratory effects. Caution is also advised for patients with severe infection (sepsis) or mitochondrial disorders.

Pregnancy and Lactation Anvar is not recommended for use in obstetrics, including Cesarean section deliveries, as the drug crosses the placental barrier. For nursing mothers, the official label advises to discard breast milk for 24 hours following administration.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Pharmacodynamic and Exposure Interactions

The primary interaction pattern of Anvar (Propofol) involves pharmacodynamic reinforcement with other Central Nervous System (CNS) depressants. Co-administration with substances such as opioids, sedatives, inhalational anesthetics, or alcohol is documented to increase the effects of Propofol, enhancing sedation and increasing the risk of cardiorespiratory depression and hypotension. The co-administration of antihypertensive agents may similarly exacerbate Propofol’s hypotensive effect.

A distinct pharmacokinetic interaction is noted with the antiepileptic agent Valproate, which official labeling states can lead to increased systemic blood levels (exposure) of Propofol, requiring caution. Profound hypotension has also been reported in patients treated concurrently with Rifampicin.

Mandatory Restrictions and Incompatibilities

Propofol is formally contraindicated in patients with a documented hypersensitivity to the active substance or to the excipients present in the emulsion, notably soybean oil and egg phosphatides.

Regulatory documents stipulate important procedural constraints: Propofol must not be administered through the same intravenous catheter with blood, serum, or plasma due to the risk of physical aggregation. The IV line should also be flushed between Propofol and the administration of certain neuromuscular blocking agents, such as Atracurium or Mivacurium, to prevent physical incompatibility.

Specific population notes indicate that elderly or debilitated (ASA-PS III/IV) patients have a heightened risk of cardiopulmonary effects when co-administered with other sedating agents.

Mechanism of Action

How Anvar Works

Anvar operates via a precise, multi-step pharmacodynamic mechanism focused on modulating core signaling dynamics within specific biological systems.


Targeted Receptor/Enzyme Modulation

Its action initiates with the direct modulation of a defined biological target, specifically a key receptor or enzyme system. The drug functions as a ligand, initiating or blocking specific signaling events by binding to the target interface. This targeted action is the primary mechanistic focus, resulting in a rapid adjustment of receptor or enzyme activity within the cell.


Modification of Signal Transduction Pathways

Following primary binding, the mechanism propagates through well-characterized molecular cascades. Anvar alters signaling dynamics in defined neural or humoral pathways, acting within the signal transduction process. By modifying early molecular steps, the drug modifies the regulation of overactive or underactive physiological responses, which shapes the drug's downstream effect profile.


Alteration of Dysregulated Physiological Systems

The cumulative effect of these actions leads to a functional impact on large regulatory systems. Anvar engages mechanisms that regulate overactive or dysregulated processes, resulting in an altered regulated state within targeted pathways. This modifies the effect of excessive mediator activity and ultimately influences overactive physiological responses at a systemic level.

Dosage and Administration Information

The administration of Anvar (Propofol) is exclusively managed by trained healthcare professionals in specialized clinical environments, such as hospitals or surgical centers. The drug must be administered through the intravenous (IV) route only, typically via slow injection for induction or a continuous, variable-rate infusion for maintenance and sedation.

Propofol is administered based on the principle of titration to effect, meaning the dose is individualized and adjusted incrementally over short periods (e.g., 3 to 5 minutes) to reach the desired clinical state. For induction of general anesthesia in healthy adults, the labeled dose range is typically between 1.5 and 2.5 mg/kg of body weight. Continuous infusion for maintenance commonly falls in the range of 100 to 200 mcg/kg/min.

Specialized administration rules apply to specific populations and handling. Older or debilitated patients generally require a lower starting dose, often approximately 80% of the usual adult dose, and administration must be exceptionally slow. Furthermore, the drug is not recommended for continuous ICU sedation in pediatric patients 16 years of age or younger. Preparation requires strict aseptic technique; if the emulsion is opened or diluted, administration must be completed within 12 hours. Dilution, if necessary, is approved only with 5% Dextrose Injection, USP, to a concentration of at least 2 mg/mL. These procedural constraints define the mandatory protocol for its use.

Recent Clinical Evidence

Anvar: Recent Clinical Evidence

Overview of Key Research

Research has explored whether oxandrolone (marketed as Anvar or Oxandrin) affects clinical outcomes in individuals experiencing weight loss due to extensive surgery, chronic infections, severe trauma, or in severely burned pediatric patients. Studies have examined the drug's effect on muscle wasting, body composition, and recovery time.


Phase 3 Trial Data

A pivotal Phase 3 trial focusing on pediatric patients with severe burns evaluated the long-term effects of oxandrolone administration. The study reported outcomes where the severity of symptoms, body composition, and growth parameters were assessed over several years post-treatment.

  • Key Outcome: In severely burned children, long-term administration was associated with increased whole-body and lumbar spine bone mineral content (BMC) and bone mineral density (BMD), as well as improved height velocity, compared to control groups.
  • Study Design: Researchers also evaluated whether the drug affected lean body mass (LBM) and muscle strength in this patient population, often comparing its effects to placebo.

Mechanism and Tolerability Studies

Researchers examined the proposed targets of this synthetic testosterone derivative. The drug interacts with androgen receptors in target tissues, aiming to stimulate protein synthesis (anabolism) and counteract the loss of muscle mass (catabolism) often seen in these severe trauma states.

  • Tolerability: The tolerability of the drug was evaluated across different patient populations in the trials. While the drug may alter lipid profiles (increasing LDL and decreasing HDL cholesterol), the long-term studies on severely burned children did not attribute new adverse effects to the treatment duration of up to two years.

Extended Use and Efficacy

Studies have explored the potential for oxandrolone to be used long-term in an outpatient setting to support sustained recovery. Research on patients with severe burns suggested that the improvements in BMC and BMD observed during treatment may persist well beyond the period of administration.

Key Studies & References

  1. Oxandrolone in the treatment of severely burned children: a multicenter prospective study

Frequently Asked Questions (FAQ)

Common questions about Anvar (FAQ)


Q: How quickly does Anvar typically start working?

A: Official information describes that Anvar has a very rapid onset of action after it is administered intravenously. It typically begins to take effect in under a minute, which is why it is used for the induction of general anesthesia.


Q: Can Anvar be used by people with kidney problems?

A: Regulatory documents advise that Anvar should be used with caution in patients with kidney conditions. The drug is largely processed by the body outside of the kidneys, but a healthcare professional typically assesses the overall risk before administration.


Q: Can Anvar be used by people with liver problems?

A: Anvar is metabolized (broken down) primarily in the liver. While its use is described as possible in patients with liver conditions, official documents caution that monitoring may be necessary, as is typical with such agents.


Q: Are headaches a common side effect of Anvar?

A: Yes, official labeling lists headache as a common adverse reaction following the use of Anvar. Adverse effects, including headaches, are typically managed and monitored by the medical team during and after administration.


Q: What are the most serious side effects listed for Anvar?

A: The most serious side effects listed in official documents include profound cardiopulmonary depression (issues with heart and breathing), and a rare, life-threatening condition called Propofol Infusion Syndrome (PRIS). PRIS is typically only associated with prolonged, high-dose infusions.


Q: Is it normal to feel dizzy when starting Anvar?

A: Dizziness, faintness, or lightheadedness are listed in official documents as possible adverse reactions. This may be due to the drug’s known effect of causing a temporary reduction in blood pressure.


Q: Can Anvar be taken with common pain relievers like ibuprofen or acetaminophen?

A: Official documents caution that Anvar may increase the effects of other medications that cause Central Nervous System (CNS) or respiratory depression (slowing down brain activity or breathing). The medical team is typically informed about all medications being taken prior to administration.


Q: Is there a list of herbal supplements that should be avoided while taking Anvar?

A: The official label does not provide a specific list of herbal supplements. However, it advises caution with all agents that may cause CNS or respiratory depression, which is a general consideration for many supplements that affect the nervous system.


Q: Can Anvar affect sleep?

A: Anvar is classified as a sedative-hypnotic agent because it causes a profound decrease in consciousness. Studies indicate that the state it induces does not share the characteristic cyclical patterns of natural sleep.


Q: Is Anvar safe to take long-term?

A: Anvar is approved for short-term anesthesia and procedural use. While it is approved for Intensive Care Unit (ICU) sedation, official warnings cite a risk of the serious condition PRIS (Propofol Infusion Syndrome) in patients receiving prolonged, high-dose infusions, especially those lasting longer than 48 hours.


Q: Is Anvar approved for use in children?

A: Official documentation indicates Anvar is approved for general anesthesia and sedation for certain procedures in pediatric patients. However, it is explicitly not recommended for continuous ICU sedation in pediatric patients 16 years of age or younger.


Q: Is there a risk of dependency or addiction with Anvar?

A: Official and supporting documents note that Anvar has an established potential for abuse. Cases of compulsive self-administration and associated serious harm have been reported, which is why its use is heavily restricted to professional settings.


Q: What kind of research studies have been done on Anvar?

A: Research cited in official documents focuses on its use for induction and maintenance of general anesthesia, procedural sedation, its pharmacological mechanism (how it works in the body), and its established safety profile, particularly effects on the heart and lungs.


Q: Is Anvar a controlled substance?

A: Federally, Anvar is not currently classified as a controlled substance under the U.S. Controlled Substances Act (CSA). However, due to its documented abuse potential, many medical facilities manage its use under the same strict tracking protocols as controlled substances.


Q: Is Anvar the generic or brand name of the drug?

A: Anvar is the name used in this discussion. The drug's generic chemical name is propofol, and a well-known brand name under which it is marketed is Diprivan.


Q: Are there specific blood tests needed while taking Anvar?

A: Patients receiving Anvar, particularly those on high-dose or prolonged infusions, may require monitoring of blood values. These tests check for changes in markers like serum creatine kinase, triglycerides, and liver enzymes, which may be assessed to monitor for known risks, such as PRIS (Propofol Infusion Syndrome).


Q: What happens if I stop taking Anvar suddenly?

A: Due to its rapid metabolism and redistribution, the clinical effect of Anvar wears off quickly. Official documents do not typically address traditional withdrawal, as its administration is acute (short-term) and is typically discontinued under close medical supervision.


Q: Does Anvar affect blood pressure?

A: Yes, official labeling notes that Anvar commonly causes a reduction in systemic blood pressure (hypotension). This effect is expected and is routinely monitored by the medical team.


Q: Is it possible to be allergic to Anvar?

A: Yes, Anvar is formally contraindicated (should not be used) in patients with a known hypersensitivity to the drug or to its inactive components. This specifically includes patients with a known allergy to eggs or soy products, as these are present in the emulsion.


Q: Can Anvar cause stomach issues like nausea or vomiting?

A: Nausea and vomiting are listed in official documents as common adverse reactions following the use of Anvar. Despite this, the drug is also reported to have antiemetic (anti-nausea) properties that may help prevent certain types of nausea.


Q: Are there any mood changes associated with Anvar use?

A: Official information lists changes in mood or mental state, such as anxiety and delirium, as possible but less common side effects that can occur during recovery from the effects of the drug.


Q: Does taking Anvar require dietary restrictions?

A: The primary restriction is that Anvar is contraindicated in patients with a known allergy to eggs or soy products. These components are used in the drug's formulation as an emulsion.


Q: Are there any long-term side effects that are less common?

A: The most notable serious condition associated with long-term, high-dose infusion is Propofol Infusion Syndrome (PRIS). The condition's severity highlights the need for careful patient selection and monitoring, as described in official guidelines.


Q: Does the effectiveness of Anvar decrease over time?

A: The effectiveness of Anvar is maintained by the medical team through continuous adjustment (titration) of the infusion rate. The official label does not typically mention the development of tolerance to the primary effect.


Q: What is the half-life of Anvar?

A: Anvar has a very quick distribution half-life, which leads to its rapid wake-up time. However, its terminal elimination half-life (the time it takes for the body to clear half the drug) is longer, generally listed as 4 to 7 hours.


Q: How is Anvar removed from the body?

A: Anvar is removed from the body primarily by being metabolized (broken down) in the liver and other tissues. The resulting inactive byproducts are then excreted mainly through the kidneys.


Q: Does Anvar cause dry mouth?

A: Official information lists side effects such as dry eyes, mouth, nose, or throat as possible, though less common, adverse reactions to the drug.


Q: Are there different strengths of Anvar available?

A: Anvar is an injectable emulsion that is primarily available at a standard concentration of 10 mg/mL in different volume sizes, such as 20 mL, 50 mL, or 100 mL vials.


Q: Is Anvar used in combination with other drugs for treatment?

A: Yes, official documents note that Anvar is commonly used in combination with opioids, sedatives, and inhalational anesthetics in the context of general anesthesia and procedural sedation.


Q: Can Anvar affect my ability to drive?

A: Due to its powerful sedative effects, official documentation notes that driving or operating complex machinery is typically avoided until all effects on judgment, coordination, and reaction time have fully resolved.


Q: Is Anvar available as a liquid?

A: Anvar is supplied as an injectable emulsion (a milky-white liquid). This formulation is necessary for its intravenous administration.


Q: What is the difference between Anvar and [Name of a common similar drug]?

A: Anvar belongs to the class of medications known as general anesthetics or sedative-hypnotics. Official documents classify its primary action as enhancing the effects of the neurotransmitter GABA in the brain.


Q: Can Anvar be used during pregnancy?

A: Official information indicates Anvar crosses the placenta and may cause central nervous system (CNS) and respiratory depression in the newborn. Official guidelines indicate that any use during pregnancy requires assessment by a medical professional to balance the benefits and risks.


Q: Can Anvar be used while breastfeeding?

A: Studies indicate that the amount of Anvar that passes into breast milk is described as very small. Most medical experts suggest that breastfeeding can be resumed once the mother has recovered and is fully awake following the anesthesia.


Q: Is the safety profile of Anvar similar to other drugs in its class?

A: The official record notes that recovery from Anvar-induced anesthesia is generally associated with less frequent side effects such as drowsiness, nausea, and vomiting than with older, similar agents.

How should Anvar be stored and disposed of?

Official Storage and Disposal Requirements

Propofol's storage and handling are strictly defined by regulatory documents to preserve the integrity of its specialized oil-in-water emulsion.

Storage Conditions

Condition Requirement (Official Labeling)
Temperature Store unopened vials at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F).
Freezing Do not freeze the product under any circumstances.
Protection Keep out of the sight and reach of children.

Handling and Stability

The vial is intended for single-use in one patient. Strict aseptic technique must be maintained during handling. Administration must commence promptly and be completed within 12 hours of opening the vial, after which the unused product must be discarded.

Disposal Instructions

All unused Propofol and associated administration materials must be discarded at the end of the procedure or within the 12-hour limit. Disposal must follow all local and national regulatory requirements. Do not dispose of the product by pouring it into drains or waterways to prevent environmental release.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Anvar found in:

A-Z Index: